Why Is Garden Stage Stock Shooting Up 21.83% In After-Hours?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Should l Buy GSIW?
Source: Benzinga
Stock Performance: Garden Stage Ltd (GSIW) experienced a 21.83% increase in stock value after announcing a $4.2 million direct offering of shares at $0.11 each, closing at $0.13 during after-hours trading.
Market Context: The stock has had a volatile month, previously dropping 37.6% before resuming trading after regaining NASDAQ compliance, and the recent offering aims to stabilize its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSIW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSIW
About GSIW
Garden Stage Ltd is a holding company principally engaged in the provision of financial services. The Company is principally engaged in the provision of securities dealing and brokerage services, securities underwriting and placing services, asset management services as well as others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points
- Dow Jones Performance: The Dow Jones index gained over 100 points on Wednesday, rising 0.25% to close at 48,622.74, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.69% to 22,672.12, while the S&P 500 rose 0.37% to 6,841.53, reflecting strong performances in the technology and consumer sectors.
- Abercrombie & Fitch Earnings: The company reported Q4 earnings of $3.68 per share, beating analyst expectations of $3.57, yet its stock fell around 5%, indicating market concerns about future performance.
- Private Sector Job Data: U.S. private businesses added 63,000 jobs in February, significantly exceeding market estimates of 50,000, suggesting a robust economic recovery that could positively impact the stock market.
See More
Garden Stage Limited Announces 200-for-1 Share Consolidation
- Share Consolidation Plan: Garden Stage Limited announced a 200-for-1 share consolidation effective March 6 to comply with Nasdaq Marketplace Rule 5550(a)(2), aiming to enhance investor confidence and maintain its listing status.
- Trading Symbol Unchanged: Post-consolidation, the company's Class A shares will continue trading on the Nasdaq Capital Market under the symbol 'GSIW', but with a new CUSIP number G3730L131, ensuring market liquidity and transparency.
- Change in Share Count: Before the consolidation, the company had 282,485,623 Class A shares outstanding, which is expected to reduce to approximately 1,412,428 shares post-consolidation, while Class B shares will remain unchanged at 9,250,000, reflecting the company's efforts to optimize its capital structure.
- Market Reaction: Following the consolidation announcement, GSIW's stock price fell 36.88% in pre-market trading to $0.0568, indicating market caution regarding the company's future prospects, which may impact investor confidence and subsequent financing capabilities.
See More
GARDEN STAGE LIMITED DECLARES 200 FOR 1 CONSOLIDATION OF CLASS A SHARES
- Company Announcement: Gardens Stage Limited has announced a consolidation of Class A shares.
- Share Conversion Rate: The consolidation will occur at a rate of 200 for 1 share.
See More
Garden Stage Announces Share Reclassification
- Share Reclassification Details: Garden Stage Limited announced a reclassification of its ordinary shares effective February 12, 2026, on the Nasdaq, changing its authorized share capital from $50,000 to 425,968,655 unissued Class A ordinary shares, aimed at optimizing capital structure and enhancing market competitiveness.
- Capital Structure Adjustment: Following the reclassification, 9,250,000 ordinary shares held by Oriental Moon Tree Limited will be redesignated as Class B ordinary shares, while 64,781,655 ordinary shares will become Class A ordinary shares, ensuring all shareholder rights are preserved in accordance with the company's articles of association.
- Company Operational Background: Garden Stage Limited is a holding company incorporated in the Cayman Islands, with wholly-owned subsidiaries in Hong Kong, including I Win Securities Limited and I Win Asset Management Limited, which are licensed for securities dealing and asset management, respectively, strengthening its market position in financial services.
- Forward-Looking Statements: The company included forward-looking statements in its announcement, indicating that future business strategies and financial needs may be influenced by various known and unknown risks, and while optimistic about future expectations, actual results may differ significantly, urging investors to carefully assess related risks.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points
- Dow Jones Performance: The Dow Jones index gained over 100 points on Wednesday, rising 0.25% to close at 48,622.74, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.69% to 22,672.12, while the S&P 500 rose 0.37% to 6,841.53, reflecting strong performances in the technology and consumer sectors.
- Abercrombie & Fitch Earnings: The company reported Q4 earnings of $3.68 per share, beating analyst expectations of $3.57, yet its stock fell around 5%, indicating market concerns about future performance.
- Private Sector Job Data: U.S. private businesses added 63,000 jobs in February, significantly exceeding market estimates of 50,000, suggesting a robust economic recovery that could positively impact the stock market.
See More
Garden Stage Limited Announces 200-for-1 Share Consolidation
- Share Consolidation Plan: Garden Stage Limited announced a 200-for-1 share consolidation effective March 6 to comply with Nasdaq Marketplace Rule 5550(a)(2), aiming to enhance investor confidence and maintain its listing status.
- Trading Symbol Unchanged: Post-consolidation, the company's Class A shares will continue trading on the Nasdaq Capital Market under the symbol 'GSIW', but with a new CUSIP number G3730L131, ensuring market liquidity and transparency.
- Change in Share Count: Before the consolidation, the company had 282,485,623 Class A shares outstanding, which is expected to reduce to approximately 1,412,428 shares post-consolidation, while Class B shares will remain unchanged at 9,250,000, reflecting the company's efforts to optimize its capital structure.
- Market Reaction: Following the consolidation announcement, GSIW's stock price fell 36.88% in pre-market trading to $0.0568, indicating market caution regarding the company's future prospects, which may impact investor confidence and subsequent financing capabilities.
See More
GARDEN STAGE LIMITED DECLARES 200 FOR 1 CONSOLIDATION OF CLASS A SHARES
- Company Announcement: Gardens Stage Limited has announced a consolidation of Class A shares.
- Share Conversion Rate: The consolidation will occur at a rate of 200 for 1 share.
See More
Garden Stage Announces Share Reclassification
- Share Reclassification Details: Garden Stage Limited announced a reclassification of its ordinary shares effective February 12, 2026, on the Nasdaq, changing its authorized share capital from $50,000 to 425,968,655 unissued Class A ordinary shares, aimed at optimizing capital structure and enhancing market competitiveness.
- Capital Structure Adjustment: Following the reclassification, 9,250,000 ordinary shares held by Oriental Moon Tree Limited will be redesignated as Class B ordinary shares, while 64,781,655 ordinary shares will become Class A ordinary shares, ensuring all shareholder rights are preserved in accordance with the company's articles of association.
- Company Operational Background: Garden Stage Limited is a holding company incorporated in the Cayman Islands, with wholly-owned subsidiaries in Hong Kong, including I Win Securities Limited and I Win Asset Management Limited, which are licensed for securities dealing and asset management, respectively, strengthening its market position in financial services.
- Forward-Looking Statements: The company included forward-looking statements in its announcement, indicating that future business strategies and financial needs may be influenced by various known and unknown risks, and while optimistic about future expectations, actual results may differ significantly, urging investors to carefully assess related risks.
See More
